| Date |
Article |
|
Site |
| 07:58 |
Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom |
|
medwatch (en) |
| 03/10 |
Novo Nordisk's semaglutide to be studied for positive effect on alcoholics |
|
medwatch (en) |
| 03/10 |
Olympus appoints new chief medical officer |
|
medwatch (en) |
| 03/10 |
Low share price may knock Galecto off the stock exchange |
|
medwatch (en) |
| 03/10 |
Fujifilm expands management with former Leo executive |
|
medwatch (en) |
| 03/10 |
Snack maker keeps an eye on Novo Nordisk's obesity drug |
|
medwatch (en) |
| 02/10 |
FDA approves Novo Nordisk drug to treat rare condition |
|
medwatch (en) |
| 02/10 |
FDA updates Novo Nordisk's Ozempic drug label with side effect alert |
|
medwatch (en) |
| 02/10 |
FDA rejects atopic dermatitis drug lebrikizumab |
|
medwatch (en) |
| 02/10 |
FDA to support new orphan drugs through pilot program |
|
medwatch (en) |
| 02/10 |
Vaccine breakthrough behind mRNA shots wins Nobel Prize |
|
medwatch (en) |
| 02/10 |
WS Audiology hires new chief technology officer from car manufacturer |
|
medwatch (en) |
| 02/10 |
Country Manager: Indians will have to wait for Wegovy until 2026 |
|
medwatch (en) |
| 02/10 |
Novo Nordisk files lawsuit against US authorities ahead of price negotiation |
|
medwatch (en) |
| 29/09 |
Genmab has officially opened its new headquarters |
|
medwatch (en) |
| 29/09 |
Analyst: Only natural for new GN CEO to form his own team |
|
medwatch (en) |
| 29/09 |
Johnson & Johnson shows positive results in lung cancer study |
|
medwatch (en) |
| 29/09 |
Novo Holdings makes another investment in US biotech company |
|
medwatch (en) |
| 29/09 |
GN sets new management team after merger and launches new division |
|
medwatch (en) |
| 28/09 |
New GN platform completes ten years of connectivity work |
|
medwatch (en) |
| 28/09 |
Kallyope enters Phase II with obesity and diabetes tablet |
|
medwatch (en) |
| 28/09 |
EU lags behind the US and China in artificial intelligence |
|
medwatch (en) |
| 28/09 |
GN launches new product platform |
|
medwatch (en) |
| 28/09 |
GN secures credit facilities of additional DKK 3.4bn |
|
medwatch (en) |
| 27/09 |
Galecto to lay off 70% of its workforce - announces plans to explore "strategic alternatives" |
|
medwatch (en) |
| 27/09 |
Edwards Lifesciences subject to unannounced EU inspection |
|
medwatch (en) |
| 27/09 |
Investor alliance urges pharmaceutical companies to improve environmental impact |
|
medwatch (en) |
| 27/09 |
Minister: Several countries are against key proposal in controversial EU reform |
|
medwatch (en) |
| 27/09 |
Ascendis CFO sells shares worth DKK millions |
|
medwatch (en) |
| 27/09 |
Novo Nordisk to limit access to Wegovy in new markets |
|
medwatch (en) |
| 26/09 |
Novo Nordisk to expand pipeline through new acquisitions |
|
medwatch (en) |
| 26/09 |
Former Xellia CEO becomes chairman of biotech company on capital hunt |
|
medwatch (en) |
| 26/09 |
Parallel importer Abacus upgrades full-year outlook |
|
medwatch (en) |
| 26/09 |
Jefferies: Wegovy sales may disappoint in the third quarter |
|
medwatch (en) |
| 26/09 |
Novo CEO: Unlikely that public reimbursement will cover all Wegovy patients |
|
medwatch (en) |
| 25/09 |
Genmab and Abbvie receives EU clearance to market cancer drug |
|
medwatch (en) |
| 25/09 |
Novo Nordisk enters billion-dollar partnership with Valo Health |
|
medwatch (en) |
| 25/09 |
Japanese authorities approve cancer drug by Genmab and Abbvie |
|
medwatch (en) |
| 25/09 |
MC2 Therapeutics secures exclusive option rights to new drug candidate |
|
medwatch (en) |
| 25/09 |
Novo Nordisk appoints new general counsel |
|
medwatch (en) |
| 25/09 |
Radiometer has launched its own version of ChatGPT |
|
medwatch (en) |
| 25/09 |
Analyst predicts USD 100bn obesity drug market by 2035 |
|
medwatch (en) |
| 25/09 |
Bank downplays importance of patent dispute and FDA notice to Novo Nordisk |
|
medwatch (en) |
| 25/09 |
Kåre Schultz in new book: Lundbeck was about to drop major collaboration |
|
medwatch (en) |
| 25/09 |
Investment bank sees Eli Lilly dominating the obesity market in the 2030s |
|
medwatch (en) |
| 22/09 |
European trade association calls for comprehensive reform of MDR and IVDR |
|
medwatch (en) |
| 22/09 |
Kåre Schultz: Former chairman of Novo Nordisk Foundation cost me the job as Novo Nordisk CEO |
|
medwatch (en) |
| 22/09 |
Jyske Bank questions Demant's continued momentum |
|
medwatch (en) |
| 22/09 |
Third time's the charm: Novo Nordisk makes new bid to get obesity drug reimbursed in Danish home market |
|
medwatch (en) |
| 22/09 |
Novo Holdings completes acquisition of US antibiotics company for DKK 3.2bn |
|
medwatch (en) |